Vedrørende selvmordsfare konkluderede CHMP, at den nuværende advarsel i produktoplysningerne allerede oplyser læger og forældre om, at patienterne nøje skal overvåges for tegn på selvmordsrelateret, selvbeskadigende eller fjendtlig adfærd, navnlig ved behandlingens indledning.
In relation to suicidality, the CHMP concluded that the current warning of the product information already informs doctors and parents to monitor patients carefully for the appearance of suicidal behaviour, self-harm or hostility, particularly at the beginning of treatment.